Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial.

Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR

Diabetes care1 Jun 2004Cited by 208 (Europe PMC)

PMID15161785DOI10.2337/diacare.27.6.1335PepBankPUB-15161785

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In outpatients with type 2 diabetes, liraglutide 0.75 mg decreased HbA1c by 0.75 percentage points versus placebo at 12 weeks.
In plain wordsIn people with type 2 diabetes, liraglutide 0.75 mg lowered HbA1c more than placebo after 12 weeks.
Peptide
Liraglutide
Outcome
DecreaseHbA1c change at week 12 (0.75 mg)
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 mg once daily · 12 weeksAs given in this study (human).
Measurements
HbA1c difference
−0.75 percentage points
liraglutide 0.75 mg vs placebo
Source sentences
Summary
In the 0.75-mg liraglutide group, HbA(1c) decreased by 0.75 percentage points (P < 0.0001) and fasting glucose decreased by 1.8 mmol/l (P = 0.0003) compared with placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
A double-blind, randomized, parallel-group, placebo-controlled trial with an open-label comparator arm was conducted among 193 outpatients with type 2 diabetes.
Summary · context
Patients were randomly assigned to one of five fixed-dosage groups of liraglutide (0.045, 0.225, 0.45, 0.60, or 0.75 mg), placebo, or open-label sulfonylurea (glimepiride, 1-4 mg).
Report a problemFND-1516178501
02HumanRandomized controlled trialEfficacy outcome
In outpatients with type 2 diabetes, liraglutide 0.75 mg decreased fasting glucose by 1.8 mmol/l versus placebo.
In plain wordsIn people with type 2 diabetes, liraglutide 0.75 mg lowered fasting blood sugar more than placebo.
Peptide
Liraglutide
Outcome
DecreaseFasting glucose (0.75 mg)
Study
n: not reported in source
Comparator
Placebo
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 mg once daily · 12 weeksAs given in this study (human).
Measurements
Fasting glucose difference
−1.8 mmol/l
liraglutide 0.75 mg vs placebo
Source sentences
Summary
In the 0.75-mg liraglutide group, HbA(1c) decreased by 0.75 percentage points (P < 0.0001) and fasting glucose decreased by 1.8 mmol/l (P = 0.0003) compared with placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
A double-blind, randomized, parallel-group, placebo-controlled trial with an open-label comparator arm was conducted among 193 outpatients with type 2 diabetes.
Summary · context
Patients were randomly assigned to one of five fixed-dosage groups of liraglutide (0.045, 0.225, 0.45, 0.60, or 0.75 mg), placebo, or open-label sulfonylurea (glimepiride, 1-4 mg).
Report a problemFND-1516178503
03HumanRandomized controlled trialEfficacy outcome
In outpatients with type 2 diabetes, body weight decreased by 1.2 kg with liraglutide 0.45 mg compared with placebo.
In plain wordsIn people with type 2 diabetes, liraglutide 0.45 mg lowered body weight more than placebo.
Peptide
Liraglutide
Outcome
DecreaseBody weight (0.45 mg)
Study
n: not reported in source
Comparator
Placebo
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
0.45 mg once daily · 12 weeksAs given in this study (human).
Measurements
Body weight change
−1.2 kg
liraglutide 0.45 mg vs placebo
Source sentences
Summary
Body weight decreased by 1.2 kg in the 0.45-mg liraglutide group (P = 0.0184) compared with placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
A double-blind, randomized, parallel-group, placebo-controlled trial with an open-label comparator arm was conducted among 193 outpatients with type 2 diabetes.
Summary · context
Patients were randomly assigned to one of five fixed-dosage groups of liraglutide (0.045, 0.225, 0.45, 0.60, or 0.75 mg), placebo, or open-label sulfonylurea (glimepiride, 1-4 mg).
Report a problemFND-1516178505
04HumanRandomized controlled trialEfficacy outcome
In outpatients with type 2 diabetes, HbA1c decreased in all liraglutide dose groups except the lowest.
In plain wordsIn people with type 2 diabetes, HbA1c fell in every liraglutide dose group except the lowest dose.
Peptide
Liraglutide
Outcome
DecreaseHbA1c decrease across liraglutide doses
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.225-0.75 mg once daily · 12 weeksAs given in this study (human).
Source sentences
Summary
HbA(1c) decreased in all but the lowest liraglutide dosage group.
2 context sentences(design, population, supporting numbers)
Summary · context
A double-blind, randomized, parallel-group, placebo-controlled trial with an open-label comparator arm was conducted among 193 outpatients with type 2 diabetes.
Summary · context
Patients were randomly assigned to one of five fixed-dosage groups of liraglutide (0.045, 0.225, 0.45, 0.60, or 0.75 mg), placebo, or open-label sulfonylurea (glimepiride, 1-4 mg).
Report a problemFND-1516178502
05HumanRandomized controlled trialEfficacy outcome
In outpatients with type 2 diabetes, improvement in glycemic control with liraglutide was evident after 1 week.
In plain wordsIn people with type 2 diabetes, blood sugar control improved within one week of liraglutide.
Peptide
Liraglutide
Outcome
Direction not reportedTime to glycemic improvement
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.045-0.75 mg once daily · 12 weeksAs given in this study (human).
Source sentences
Summary
Improvement in glycemic control was evident after 1 week.
2 context sentences(design, population, supporting numbers)
Summary · context
A double-blind, randomized, parallel-group, placebo-controlled trial with an open-label comparator arm was conducted among 193 outpatients with type 2 diabetes.
Summary · context
Patients were randomly assigned to one of five fixed-dosage groups of liraglutide (0.045, 0.225, 0.45, 0.60, or 0.75 mg), placebo, or open-label sulfonylurea (glimepiride, 1-4 mg).
Report a problemFND-1516178504
06HumanRandomized controlled trialEfficacy outcome
In outpatients with type 2 diabetes, the proinsulin-to-insulin ratio decreased with liraglutide 0.75 mg compared with placebo.
In plain wordsIn people with type 2 diabetes, liraglutide 0.75 mg lowered the proinsulin to insulin ratio more than placebo.
Peptide
Liraglutide
Outcome
DecreaseProinsulin-to-insulin ratio (0.75 mg)
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
0.75 mg once daily · 12 weeksAs given in this study (human).
Measurements
Proinsulin-to-insulin ratio change
−0.18 ratio
liraglutide 0.75 mg vs placebo
Source sentences
Summary
The proinsulin-to-insulin ratio decreased in the 0.75-mg liraglutide group (-0.18; P = 0.0244) compared with placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
A double-blind, randomized, parallel-group, placebo-controlled trial with an open-label comparator arm was conducted among 193 outpatients with type 2 diabetes.
Summary · context
Patients were randomly assigned to one of five fixed-dosage groups of liraglutide (0.045, 0.225, 0.45, 0.60, or 0.75 mg), placebo, or open-label sulfonylurea (glimepiride, 1-4 mg).
Report a problemFND-1516178506
07HumanRandomized controlled trialSafety outcome
In outpatients with type 2 diabetes, no safety issues were raised for liraglutide, and observed adverse events were mild and transient.
In plain wordsIn people with type 2 diabetes, liraglutide raised no safety issues; side effects were mild and short-lived.
Peptide
Liraglutide
Outcome
Not applicableAdverse events
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
0.045-0.75 mg once daily · 12 weeksAs given in this study (human).
Source sentences
Summary
No safety issues were raised for liraglutide; observed adverse events were mild and transient.
2 context sentences(design, population, supporting numbers)
Summary · context
A double-blind, randomized, parallel-group, placebo-controlled trial with an open-label comparator arm was conducted among 193 outpatients with type 2 diabetes.
Summary · context
Patients were randomly assigned to one of five fixed-dosage groups of liraglutide (0.045, 0.225, 0.45, 0.60, or 0.75 mg), placebo, or open-label sulfonylurea (glimepiride, 1-4 mg).
Report a problemFND-1516178507

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2NCT01509755

Comparison of Liraglutide and Glimepiride on Blood Sugar Control in Subjects With Type 2 Diabetes

Novo Nordisk A/Sn = 196Oct 2000 to Oct 2001

Diabetes · Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 24 Jan 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.